Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 4:52 pm Sale | 2025-11-14 | 13D | BridgeBio Pharma, Inc. BBIO | VIKING GLOBAL INVESTORS LP | 15,893,934 8.200% | -2,708,986 (-14.56%) | Filing History |
| 2025-11-14 12:19 pm Purchase | 2025-09-30 | 13G | BridgeBio Oncology Therapeutics Inc. BBOT | T. Rowe Price Associates, Inc. | 885,042 1.100% | 885,042 (New Position) | Filing History |
| 2025-08-14 8:32 pm Unchanged | 2025-08-14 | 13D | BridgeBio Pharma, Inc. BBIO | VIKING GLOBAL INVESTORS LP | 18,602,920 9.700% | 0 (Unchanged) | Filing History |
| 2025-07-29 11:20 am Purchase | 2025-06-30 | 13G | BridgeBio Pharma, Inc. BBIO | VANGUARD GROUP INC | 16,484,985 8.680% | 3,684,691 (+28.79%) | Filing History |
| 2025-07-01 7:49 pm Sale | 2025-06-27 | 13D | BridgeBio Pharma, Inc. BBIO | VIKING GLOBAL INVESTORS LP | 18,602,920 9.800% | -3,452,455 (-15.65%) | Filing History |
| 2025-05-14 5:52 pm Sale | 2025-05-12 | 13D | BridgeBio Pharma, Inc. BBIO | KKR Genetic Disorder L.P. | 13,260,971 7.000% | -6,000,000 (-31.15%) | Filing History |
| 2025-03-12 4:28 pm Unchanged | 2025-01-31 | 13D | BridgeBio Pharma, Inc. BBIO | VIKING GLOBAL INVESTORS LP | 22,055,375 11.700% | 0 (Unchanged) | Filing History |
| 2025-03-07 6:15 pm Sale | 2025-03-05 | 13D | BridgeBio Pharma, Inc. BBIO | KKR Genetic Disorder L.P. | 19,260,971 10.100% | -6,000,000 (-23.75%) | Filing History |
| 2025-02-13 5:23 pm Purchase | 2024-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | Kumar Neil | 10,466,712 5.410% | 507,208 (+5.09%) | Filing History |
| 2025-01-31 7:18 pm Sale | 2025-01-31 | 13D | BridgeBio Pharma, Inc. BBIO | VIKING GLOBAL INVESTORS LP | 22,055,375 11.700% | -3,065,616 (-12.20%) | Filing History |
| 2024-11-12 11:44 am Unchanged | 2024-09-30 | 13G | BridgeBio Pharma, Inc. BBIO | BlackRock Inc. BLK | 12,878,839 6.800% | 0 (Unchanged) | Filing History |
| 2024-11-06 5:04 pm Unchanged | 2024-08-16 | 13D | BridgeBio Pharma, Inc. BBIO | VIKING GLOBAL INVESTORS LP | 25,120,991 13.400% | 0 (Unchanged) | Filing History |
| 2024-10-22 6:06 pm Purchase | 2024-09-30 | 13G | BridgeBio Pharma, Inc. BBIO | BlackRock Inc. BLK | 12,878,839 6.800% | 2,722,066 (+26.80%) | Filing History |
| 2024-09-17 6:41 pm Sale | 2024-09-13 | 13D | BridgeBio Pharma, Inc. BBIO | KKR Genetic Disorder L.P. | 25,260,971 13.400% | -5,800,000 (-18.67%) | Filing History |
| 2024-08-20 8:42 pm Unchanged | 2024-08-16 | 13D | BridgeBio Pharma, Inc. BBIO | VIKING GLOBAL INVESTORS LP | 25,120,991 13.400% | 0 (Unchanged) | Filing History |
| 2024-02-16 7:15 pm Purchase | 2023-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | Kumar Neil | 9,959,504 5.590% | 135,596 (+1.38%) | Filing History |
| 2024-02-13 5:00 pm Purchase | 2023-12-29 | 13G | BridgeBio Pharma, Inc. BBIO | VANGUARD GROUP INC | 12,800,294 7.360% | 2,208,839 (+20.85%) | Filing History |
| 2024-01-29 5:25 pm Purchase | 2023-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | BlackRock Inc. BLK | 10,156,773 5.800% | 322,372 (+3.28%) | Filing History |
| 2024-01-23 10:16 am Sale | 2023-12-31 | 13G | BridgeBio Pharma, Inc. BBIO | STATE STREET CORP STT | 5,086,899 2.920% | -3,758,044 (-42.49%) | Filing History |
| 2023-11-22 4:15 pm Unchanged | 2023-07-18 | 13D | BridgeBio Pharma, Inc. BBIO | VIKING GLOBAL INVESTORS LP | 25,120,991 15.700% | 0 (Unchanged) | Filing History |